Cytokinetics' Aficamten Hits Key Endpoints in Non-Obstructive HCM Trial

Event summary

  • Cytokinetics' aficamten met dual primary endpoints in the ACACIA-HCM Phase 3 trial for non-obstructive hypertrophic cardiomyopathy (HCM).
  • The trial showed statistically significant improvements in KCCQ-CSS and maximal exercise performance (pVO2) compared to placebo.
  • No new safety signals were identified, though 10% of aficamten patients experienced LVEF <50%.
  • Cytokinetics plans to discuss results with the FDA and present at an upcoming medical meeting.

The big picture

Cytokinetics' success in the ACACIA-HCM trial marks a significant step in addressing a currently untreated form of hypertrophic cardiomyopathy. With no approved therapies for non-obstructive HCM, aficamten could capture a substantial portion of the estimated 400,000-800,000 undiagnosed patients in the U.S. alone. The results also reinforce the company's leadership in cardiac myosin inhibitors, a growing area of cardiovascular drug development.

What we're watching

Regulatory Pathway
Whether the FDA will expedite approval for aficamten in non-obstructive HCM given the positive trial results.
Market Expansion
The pace at which Cytokinetics can expand aficamten's use beyond obstructive HCM into the non-obstructive segment.
Competitive Dynamics
How this success positions Cytokinetics against competitors developing treatments for hypertrophic cardiomyopathy.

Related topics

Drug Development